tcf-no-longer-accepting-cases

A growing number of lawsuit have been filed by people with hepatitis C whose health insurers denied coverage for Sovaldi, a new drug that can cure over 90% of patients.

Gilead Rakes in Profits as Hepatitis C Patients Seek Treatment

Gilead Sciences gained approval for Sovaldi in October 2013. Since then, it has rapidly become a blockbuster drug, generating $10 billion in 2014 alone.

While Gilead rakes in massive profits, people with hepatitis C are struggling to get coverage from their health insurance companies. Because Sovaldi is so expensive, health insurers are restricting it to patients with extreme liver damage. As a result, only a tiny fraction of the estimated 3.2 million Americans with hepatitis C are getting the treatment they need.

Sovaldi Class Action Lawsuit Filed in Pennsylvania

In December 2014, Gilead was hit with a federal class action lawsuit by the Southeastern Pennsylvania Transportation Authority (SEPTA). SEPTA accuses Gilead of “price gouging” by charging exorbitant fees for Sovaldi. The company has spent about $2.4 million to provide Sovaldi for employees and retirees, the Wall Street Journal reports.

 

About Collen

Collen A. Clark is a true advocate for his clients and is passionate about helping Texans that have been injured or wronged.

Collen A. Clark
“Collen’s amazing success in the courtroom and well known dedication to his clients has earned him the recognition of his peers as one of The Top Trial Lawyers in Texas.”

Free Confidential Case Evaluation

Verified 100% Secure SiteTo contact us for a free review of your potential case, please fill out the form below or call us toll free 24 hrs/day by dialing: (866) 879-3040.
*
*
*

Related Content on Our Website